Clinical trial
A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
NCT01217775 is registered in ClinicalTrials.gov with Pherin Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
- Lead sponsor
- Pherin Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 31, 2016
- Completion date
- July 31, 2017
- Enrollment
- 1,400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.